Emcure Pharmaceuticals Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
1
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 17, 2027The maintenance fee for Process for preparation of trientine dihydrochloride (US 10,508,075) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Stable ready-to-use carmustine pharmaceutical composition (US 11,865,206) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Process for preparation of prostacyclin derivatives (US 10,556,851) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Lipid formulations of carmustine (US 10,583,101) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,030,480 | Cost-effective process for preparation of manufacture of iron sucrose In force · From the USPTO record | In force | From the USPTO record | |
| US 9,403,809 | Synthesis of raltegravir In force · From the USPTO record | In force | From the USPTO record | |
| US 9,475,799 | Synthesis of Raltegravir In force · From the USPTO record | In force | From the USPTO record | |
| US 8,921,596 | Process for the Preparation of Melphalan Hydrochloride In force · High confidence | In force | High confidence | |
| US 9,643,914 | Fingolimod hydrochloride process In force · From the USPTO record | In force | From the USPTO record | |
| US 10,278,946 | Liquid formulation of cabazitaxel In force · From the USPTO record | In force | From the USPTO record | |
| US 10,508,075 | Process for preparation of trientine dihydrochloride In force · From the USPTO record | In force | From the USPTO record | |
| US 10,556,851 | Process for preparation of prostacyclin derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 10,583,101 | Lipid formulations of carmustine In force · From the USPTO record | In force | From the USPTO record | |
| US 10,759,738 | Process for preparation of isoproterenol hydrochloride In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 12: 13 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 no status recorded